GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
61.60 USD   +0.83%
08/08GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/05OXFORD UNIVERSITY : Oxford spinout MiroBio acquired by Gilead Sciences for $405m
AQ
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target

05/23/2022 | 06:55am EDT


© MT Newswires 2022
All news about GILEAD SCIENCES, INC.
08/08GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/05OXFORD UNIVERSITY : Oxford spinout MiroBio acquired by Gilead Sciences for $405m
AQ
08/04UBS Adjusts Gilead Sciences Price Target to $65 From $63, Maintains Neutral Rating
MT
08/04Gilead Sciences to Buy UK Biotech Firm MiroBio for $405 Million
MT
08/04Gilead Sciences to Acquire MiroBio
BU
08/04Gilead Sciences, Inc. entered into a definitive agreement to acquire MiroBio Ltd from S..
CI
08/03Health Care Up After Moderna, CVS Earnings -- Health Care Roundup
DJ
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Gilead Sciences Up Over 5%, on Pace for Largest Percent Increase Since January 2021 -- ..
DJ
08/03WALL STREET STOCK EXCHANGE : A couple of hopes dashed
MS
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 126 M - -
Net income 2022 3 912 M - -
Net Debt 2022 15 612 M - -
P/E ratio 2022 19,5x
Yield 2022 4,73%
Capitalization 77 266 M 77 266 M -
EV / Sales 2022 3,70x
EV / Sales 2023 3,68x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 61,60 $
Average target price 70,35 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-15.87%77 266
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-20.64%41 093
GENMAB A/S-2.78%22 792